Chart Predicts Whether Surgery Will Cure Prostate Cancer

May 14, 1997

Researchers at Johns Hopkins and other institutions have refined a chart that helps physicians determine how advanced a prostate cancer may be and guides treatment decisions.

The charts, called "nomograms," are a more accurate version of those developed by Hopkins researchers, according to Alan Partin, M.D., Ph.D., assistant professor of urology at the Johns Hopkins Brady Urological Institute.

The nomograms will be published in the May 14 issue of the Journal of the American Medical Association.

The nomograms combine in one chart information from three tests for prostate cancer: the clinical stage, Gleason score and PSA level. The clinical stage of cancer is found by digital rectal exam, in which the physician physically evaluates the prostate gland. The Gleason score is obtained by studying samples of the organ and its cells. The PSA level is the level of prostate specific antigen, a protein released by the gland. Higher levels of PSA suggest the gland is enlarging, perhaps due to cancer.

The newly revised nomograms were developed by using data from 4,133 men who underwent prostate cancer surgery for cancer at Johns Hopkins, Baylor University and the University of Michigan.

Current testing suggests about 60 percent of men with newly diagnosed prostate cancer have disease confined to that organ, according to Partin. "Unfortunately, after these men undergo surgery and their prostate is studied, more than half have cancer that has already spread from the prostate and may not be curable by surgery alone. The use of nomograms should improve our ability to identify those men who can best be cured by surgery alone."

"Counseling patients and helping them choose which treatment they prefer is difficult," says Partin, "because the decision depends in part on what level of risk the patient is comfortable with. A man may want surgery to remove a prostate with early cancer and risk impotence or lack of urinary control. Or he may want to avoid surgery and be treated with radiation or chemotherapy at an early stage of cancer. These nomograms are an important addition to that decision-making process."

In 1996, there were more than 317,000 new cases of prostate cancer diagnosed and more than 41,000 prostate cancer deaths.

Other authors of the study include Eric N. P. Subong and Patrick C. Walsh (Johns Hopkins), Kirk J. Wojno and Joseph E. Oesterling (University of Michigan), Michael W. Kattan and Peter T. Scardino (Baylor University, Houston, Texas), and J.D. Pearson (Merck Research Laboratories, Rahway, N.J.).

--JHMI--




Johns Hopkins Medical Institutions' news releases are available on a PRE-EMBARGOED basis on EurekAlert at http://www.eurekalert.org and from the Office of Communications and Public Affairs'direct e-mail news release service. To enroll, call 410-955-4288 or send e-mail to bpalevic@welchlink.welch.jhu.edu or 76520.560@compuserve.com.

On a POST-EMBARGOED basis find them at http://hopkins.med.jhu.edu, http://infonet.welch.jhu.edu/news/news_releases, Newswise at http://www.ari.net/newswise or on CompuServe in the SciNews-MedNews library of the Journalism Forum under file extension ".JHM", Quadnet at http://www.quad-net.com or ScienceDaily at http://www.sciencedaily.com.



Johns Hopkins Medicine

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.